On August 13, 2025, Heron Therapeutics, Inc. adopted a Tax Benefit Preservation Plan to protect its net operating losses (NOLs), declaring a dividend of preferred stock purchase rights for shareholders as of August 15, 2025. The plan aims to prevent ownership changes that could limit the NOLs' utilization, mitigating tax liabilities moving forward.